Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

This study suggests that natural killer or natural killer/T cell lineage large granular lymphocyte lymphocytosis develops in association with dasatinib therapy. Dasatinib, a dual tyrosine kinase inhibitor, is known to modulate or suppress T-cell activation and proliferation. We report a series of 8 patients who developed chronic peripheral lymphocytosis, identified as natural killer cells or natural killer/T-cells based on their large granular lymphocyte morphologies and CD16+, CD56+, CD3− or CD3+ immunophenotypic profiles, out of 18 patients receiving dasatinib therapy. All cases that developed large granular lymphocyte lymphocytosis achieved optimal molecular response (8/8 in large granular lymphocyte+ patients vs. 3/10 in large granular lymphocyte− patients, p=0.002). A 51Cr release assay demonstrated that natural killer cell cytotoxicity has been enhanced in a case of large granular lymphocyte lymphocytosis compared to normal healthy donors, and that natural killer cell cytotoxicity in dasatinib-responders was superior to that in non-responders. In summary, the present study suggests that natural killer or natural killer/T cell lineage large granular lymphocyte lymphocytosis develops in association with dasatinib therapy and that large granular lymphocyte might have a therapeutic effect on Ph+ leukemic cells.

[1]  A. Jankowska,et al.  Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. , 2008, Blood.

[2]  H. Einsele,et al.  Modulation of T-effector function by imatinib at the level of cytokine secretion. , 2007, Experimental hematology.

[3]  A. Ochsenbein,et al.  Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. , 2006, Blood.

[4]  J. Cayuela,et al.  BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia1 , 2006, The Journal of Immunology.

[5]  P. Opolon,et al.  A novel dendritic cell subset involved in tumor immunosurveillance , 2006, Nature Medicine.

[6]  J. Bourhis,et al.  The Decreased Susceptibility of Bcr/Abl Targets to NK Cell-Mediated Lysis in Response to Imatinib Mesylate Involves Modulation of NKG2D Ligands, GM1 Expression, and Synapse Formation1 , 2006, The Journal of Immunology.

[7]  A. Fischer,et al.  Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn , 2005, The Journal of experimental medicine.

[8]  S. Kamel‐Reid,et al.  T-cell large granular lymphocytic leukemia of donor origin occurring after allogeneic bone marrow transplantation for B-cell lymphoproliferative disorders. , 2005, American journal of clinical pathology.

[9]  J. Blay,et al.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.

[10]  A. Bakke,et al.  Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia , 1987, Cancer Immunology, Immunotherapy.

[11]  P. Morel,et al.  Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function 1 , 2003, The Journal of Immunology.

[12]  P. Schneider,et al.  A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors , 2002, European journal of immunology.

[13]  R. Zhao,et al.  The BCR/ABL Transgene Causes Abnormal NK Cell Differentiation and Can Be Found in Circulating NK Cells of Advanced Phase Chronic Myelogenous Leukemia Patients1 , 2002, The Journal of Immunology.

[14]  D. Olive,et al.  Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report , 2001, Bone Marrow Transplantation.

[15]  U. Mellqvist,et al.  Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. , 2000, Blood.

[16]  P. Stein,et al.  The Src Family Tyrosine Kinase Fyn Regulates Natural Killer T Cell Development , 1999, The Journal of experimental medicine.

[17]  J. Miller,et al.  CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. , 1996, Blood.

[18]  Steven M. Pincus,et al.  Generation of activated natural killer (A‐NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl‐positive targets , 1996, British journal of haematology.

[19]  C. Verfaillie,et al.  Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. , 1996, Blood.

[20]  C. Pignata,et al.  Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. , 1995, Cellular immunology.

[21]  R. Abraham,et al.  Interaction between lck and syk Family Tyrosine Kinases in Fcγ Receptor-initiated Activation of Natural Killer Cells (*) , 1995, The Journal of Biological Chemistry.

[22]  P. Pattengale,et al.  Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and productio , 1991, Natural Immunity and Cell Growth Regulation.